Sutro Biopharma, located in South San Francisco, is developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches and are beyond what can be envisioned with current (cell-based) expression technologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/08/12 | $16,500,000 | Series C |
Alta Partners Amgen Business Development | undisclosed |
